Stock NVAX NOVAVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Novavax, Inc.

Equities

NVAX

US6700024010

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		Pre-market 07:00:16 am
3.89 USD 0.00% Intraday chart for Novavax, Inc. 3.915 +0.64%
Apr. 15 Sector Update: Health Care Stocks Gain Monday Afternoon MT
Apr. 15 Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... Our Logo

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company shows low valuation levels, with an enterprise value at 0.04 times its sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
NOVAVAX, INC. Stock Novavax, Inc.
-18.96% 544M
C-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.35B
B
LONZA GROUP AG Stock Lonza Group AG
+42.61% 40.38B
A
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.05B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.07B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.36B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.6B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.68B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.15B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NVAX Stock
  4. Ratings Novavax, Inc.